[go: up one dir, main page]

AR040280A2 - Procedimiento para aumentar su solubilidad en un medio acuoso - Google Patents

Procedimiento para aumentar su solubilidad en un medio acuoso

Info

Publication number
AR040280A2
AR040280A2 ARP030102180A ARP030102180A AR040280A2 AR 040280 A2 AR040280 A2 AR 040280A2 AR P030102180 A ARP030102180 A AR P030102180A AR P030102180 A ARP030102180 A AR P030102180A AR 040280 A2 AR040280 A2 AR 040280A2
Authority
AR
Argentina
Prior art keywords
solubility
procedure
increase
water media
sertraline
Prior art date
Application number
ARP030102180A
Other languages
English (en)
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21971159&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR040280(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of AR040280A2 publication Critical patent/AR040280A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Procedimiento para aumentar la solubilidad de la sertralina en un medio de uso acuoso que contiene ion cloruro, que comprende anadir la mencionada sertralina al mencionado medio de uso en una composición de materia que adicionalmente comprende un agente solubilizante.
ARP030102180A 1997-07-01 2003-06-19 Procedimiento para aumentar su solubilidad en un medio acuoso AR040280A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US5141397P 1997-07-01 1997-07-01

Publications (1)

Publication Number Publication Date
AR040280A2 true AR040280A2 (es) 2005-03-23

Family

ID=21971159

Family Applications (3)

Application Number Title Priority Date Filing Date
ARP980103146A AR015917A1 (es) 1997-07-01 1998-06-29 Composiciones de materia que contiene sertralina y procedimiento para aumentar su solubilidad en un medio acuoso
ARP030102180A AR040280A2 (es) 1997-07-01 2003-06-19 Procedimiento para aumentar su solubilidad en un medio acuoso
ARP030102179A AR040279A2 (es) 1997-07-01 2003-06-19 Composiciones que contiene sal de sertralina

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ARP980103146A AR015917A1 (es) 1997-07-01 1998-06-29 Composiciones de materia que contiene sertralina y procedimiento para aumentar su solubilidad en un medio acuoso

Family Applications After (1)

Application Number Title Priority Date Filing Date
ARP030102179A AR040279A2 (es) 1997-07-01 2003-06-19 Composiciones que contiene sal de sertralina

Country Status (34)

Country Link
EP (1) EP0999829A1 (es)
JP (1) JP2000514100A (es)
KR (1) KR100366373B1 (es)
CN (1) CN1261794A (es)
AP (1) AP1192A (es)
AR (3) AR015917A1 (es)
AU (1) AU742535B2 (es)
BG (1) BG103918A (es)
BR (1) BR9810739A (es)
CA (1) CA2290974C (es)
CO (1) CO4940495A1 (es)
DZ (1) DZ2548A1 (es)
EA (1) EA002481B1 (es)
HN (1) HN1998000102A (es)
HR (1) HRP980377A2 (es)
HU (1) HUP0002236A3 (es)
ID (1) ID23429A (es)
IL (1) IL133076A (es)
IS (1) IS5260A (es)
MA (1) MA24587A1 (es)
NO (1) NO996520L (es)
OA (1) OA11243A (es)
PA (1) PA8454301A1 (es)
PE (1) PE97199A1 (es)
PL (1) PL337804A1 (es)
SK (1) SK181099A3 (es)
TN (1) TNSN98124A1 (es)
TR (1) TR199903297T2 (es)
TW (1) TW550087B (es)
UA (1) UA67741C2 (es)
UY (1) UY25071A1 (es)
WO (1) WO1999001120A1 (es)
YU (1) YU68299A (es)
ZA (1) ZA985708B (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TR200201617T2 (tr) 1999-12-23 2002-10-21 Pfizer Products Inc. Kuvvetlendirilmiş ilaç konsantrasyonları sağlayan farmasötik kompozisyonlar
US20030086972A1 (en) * 2000-08-09 2003-05-08 Appel Leah E. Hydrogel-driven drug dosage form
CA2420535A1 (en) 2000-08-30 2002-03-07 Mary Tanya Am Ende Sustained release formulations for growth hormone secretagogues
US20040191207A1 (en) * 2003-03-31 2004-09-30 Lipari John M. Alpha-hydroxy acid ester drug delivery compositions and methods of use
US20100105638A1 (en) * 2007-03-12 2010-04-29 Kerstin Den-Braven Cosmetic compositions
AU2010285740C1 (en) 2009-08-19 2016-03-17 Eisai R&D Management Co., Ltd. Quinoline derivative-containing pharmaceutical composition
WO2011081118A1 (ja) * 2009-12-29 2011-07-07 興和株式会社 経口投与用医薬組成物
WO2011081117A1 (ja) * 2009-12-29 2011-07-07 興和株式会社 経口投与用固形医薬組成物
CN109908354A (zh) * 2017-12-12 2019-06-21 万特制药(海南)有限公司 盐酸舍曲林口服浓缩液及其制备工艺
CN114894736B (zh) * 2022-05-20 2025-03-21 中化地质矿山总局地质研究院 一种氯化物型卤水中硝酸根的测定方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4803076A (en) * 1986-09-04 1989-02-07 Pfizer Inc. Controlled release device for an active substance
EP0415612B1 (en) * 1989-08-30 1993-11-10 Pfizer Inc. Use of sertraline for the treatment of chemical dependencies
ZA97976B (en) * 1996-04-05 1997-08-18 Alza Corp Uniform drug delivery theraphy.

Also Published As

Publication number Publication date
NO996520L (no) 2000-02-29
ZA985708B (en) 2000-01-10
HRP980377A2 (en) 1999-04-30
CO4940495A1 (es) 2000-07-24
AU7544898A (en) 1999-01-25
IS5260A (is) 1999-11-19
JP2000514100A (ja) 2000-10-24
HN1998000102A (es) 1999-01-08
KR100366373B1 (ko) 2003-01-14
UA67741C2 (uk) 2004-07-15
TR199903297T2 (xx) 2000-07-21
PA8454301A1 (es) 2000-09-29
TW550087B (en) 2003-09-01
IL133076A0 (en) 2001-03-19
PE97199A1 (es) 1999-10-05
CA2290974A1 (en) 1999-01-14
AR015917A1 (es) 2001-05-30
HUP0002236A2 (hu) 2003-08-28
AU742535B2 (en) 2002-01-03
BR9810739A (pt) 2000-09-12
EA199900962A1 (ru) 2000-08-28
AP9801280A0 (en) 1998-06-30
DZ2548A1 (fr) 2003-02-08
PL337804A1 (en) 2000-09-11
SK181099A3 (en) 2000-07-11
EP0999829A1 (en) 2000-05-17
TNSN98124A1 (fr) 2005-03-15
CN1261794A (zh) 2000-08-02
EA002481B1 (ru) 2002-06-27
KR20010013365A (ko) 2001-02-26
NO996520D0 (no) 1999-12-28
OA11243A (en) 2003-07-24
MA24587A1 (fr) 1998-12-31
AR040279A2 (es) 2005-03-23
AP1192A (en) 2003-07-23
ID23429A (id) 2000-04-20
CA2290974C (en) 2004-04-27
WO1999001120A1 (en) 1999-01-14
UY25071A1 (es) 2000-12-29
IL133076A (en) 2003-12-10
HUP0002236A3 (en) 2003-12-29
BG103918A (en) 2000-07-31
YU68299A (sh) 2002-06-19

Similar Documents

Publication Publication Date Title
MX9700082A (es) Composicion que consiste de morfina, polipirrolidona y oxido de polialquileno.
AR000714A1 (es) Un metodo de uso de un agente quelante para mejorar la fidelidad de color de telas lavadas y una composicion para uso en dicho metodo.
ES2095234T3 (es) Metodo y formulacion que emplea endoglicosidasa de tipo ii.
ES2159111T3 (es) Composiciones en pastillas para el aseo personal, que contienen un complejo liberador de fragancia.
BR9806443B1 (pt) processo e aparelho para automaticamente compensar o volume de som.
EA199900749A1 (ru) Фармацевтическая композиция
EP1057862A3 (en) Polymer film compositions for capsules
BR9703302A (pt) Aparelho e método para a geração e uso de ìons férricos
ES2185936T3 (es) Composiciones liquidas de limpieza que contienen tensioactivos ramificados en mitad de la cadena seleccionados.
CO4750807A1 (es) Solucion de interferon
AR033215A2 (es) Composicion herbicida concentrada que contiene solucion acuosa de sales de potasio y monoetanolamina de glifosato y un agente tensioactivo
NO984524D0 (no) Amfipatiske molekyler som kolesterol- og andre lipoidopptaksinhibitorer
AR021777A1 (es) UNA COMPOSICIoN PARA ACONDICIONAR, ACLARAR E ILUMINAR EL CABELLO Y UN MÉTODO PARA ACONDICIONAR, ACLARAR E ILUMINAR EL CABELLO.
AR040280A2 (es) Procedimiento para aumentar su solubilidad en un medio acuoso
HN2001000262A (es) Kit de repinotano
NL1016333A1 (nl) Elektronenstraalschrijfwerkwijze, elektronenstraallithografie-inrichting, en masker gebruikt in de werkwijze en inrichting.
ES2151135T3 (es) Compuesto pulverulento de hidroxipropil-betaciclodextrina y su procedimiento de preparacion.
MX170928B (es) Composicion limpiadora para superficies duras
BR9911464A (pt) Métodos de inibição de corrosão usando isÈmeros de cloro-metilbenzotriazol
AR020695A1 (es) Metodos para controlar macroinvertebrados en sistemas acuosos
ES2109632T3 (es) Composicion de dentifrico anhidro.
AR020703A1 (es) Barra de limpieza de superficies duras.
ES2168113T3 (es) Disolucion blanqueadora de lactona/peroxido, sistema blanqueador para formar la misma y metodo de preparacion y uso de la misma.
DK0943030T3 (da) Fremgangsmåde til reduktion af svovl- og kypefarvestoffer
ES2189150T3 (es) Composicion de revestimiento acuosa.

Legal Events

Date Code Title Description
FB Suspension of granting procedure